Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial

Lung Cancer

Volumn 69, Issue 1, 2010, Pages 86-93

  Girard, Nicolas ^a,b   Mornex, Françoise ^a,b   Douillard, Jean Yves ^b,c   Bossard, Nadine ^a   Quoix, Elisabeth ^b,d   Beckendorf, Véronique ^b,e   Grunenwald, Dominique ^b,f   Amour, Elodie ^b   Milleron, Bernard ^b,f  

^a UNIVERSITÉ LYON 1   (France)

^b French speaking Intergroup of Thoracic Oncology (IFCT)   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e CENTRE ALEXIS VAUTRIN   (France)

^f HÔPITAL TENON   (France)

Author keywords

Chemotherapy; Concomitant; Gemcitabine; Neoadjuvant treatment; Non small cell lung cancer; Paclitaxel; Radiotherapy; Vinorelbine

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; VINBLASTINE;

ADJUVANT THERAPY; ADULT; ANAPHYLAXIS; ANEMIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; THROMBOCYTOPENIA; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; FEASIBILITY STUDY; FOLLOW UP; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 77953363641     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.10.003     Document Type: Article

References (47)

1. American Cancer Society: Cancer Facts And Figures 2007, American Cancer Society, Atlanta (GA).
2. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. International association for the study of lung cancer international staging committee; participating institutions. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2:706-714.
3. Groome P.A., Bolejack V., Crowley J.J., Kennedy C., Krasnik M., Sobin L.H., et al. IASLC International Staging Committee; Cancer Research And Biostatistics; Observers To The Committee; Participating Institutions. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2:694-705.
4. Girard N., Mornex F. Radiotherapy for locally advanced non-small cell lung cancer. Eur J Cancer 2009, 45S1:113-125.
5. Andre F., Grunenwald D., Pignon J.P., Dujon A., Pujol J.L., Brichon P.Y., et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000, 18:2981-2989.
6. Martini N., Flehinger B. The role of surgery in N2 lung cancer. Surg Clin North Am 1987, 67:1037-1049.
7. Roth J., Fossella F., Komaki R. A randomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stade III non-small cell lung cancer. J Natl Cancer Inst 1994, 86:673-680.
8. Rosell R., Gomez-Codina J., Camps C., Maestre J., Padille J., Canto a, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994, 330:153-158.
9. The International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
10. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7:719-727.
11. Berghmans T., Paesmans M., Meert A.P., Mascaux C., Lothaire P., Lafitte J.J., et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005, 49:13-23.
12. Gilligan D., Nicolson M., Smith I., Groen H., Dalesio O., Goldstraw P., et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007, 369:1929-1937.
13. Depierre A., Milleron B., Moro-Sibilot D., Chevret S., Quoix E., Lebeau B., et al. French thoracic cooperative group. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002, 20:247-253.
14. Betticher D.C., Hsu Schmitz S.F., Tötsch M., Hansen E., Joss C., von Briel C., et al. Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006, 94:1099-1106.
15. Weiden P.L., Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer. A phase 2 study of the LCSG. Chest 1994, 106:344S-347S.
16. Albain K.S., Rusch V.W., Crowley J.J., Rice T.W., Turrisi A.T., Weick J.K., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995, 13:1880-1892.
17. Eberhardt W., Wilke H., Stamatis G., Stuschke M., Harstrick A., Menker H., et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998, 16:622-634.
18. Thomas M., Rübe C., Semik M., von Eiff M., Freitag L., Macha H.N., et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 1999, 17:1185-1193.
19. Stamatis G., Eberhardt W., Stuben G., Bildat S., Dahler O., Hillejan L. Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results. Ann Thorac Surg 1999, 68:1144-1149.
20. Faber L.P., Kittle C.F., Warren W.H., Bonomi P.D., Taylor S.G., Reddy S., et al. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 1989, 47:669-675.
21. Strauss G.M., Herndon J.E., Sherman D.D., Mathisen D.J., Carey R.W., Choi N.C., et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992, 10:1237-1244.
22. Deutsch M., Crawford J., Leopold K., Wolfe W., Foster W., Herndon J., et al. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. Cancer 1994, 74:1243-1252.
23. Choi N.C., Carey R.W., Daly W., Mathisen D., Wain J., Wright C., et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 1997, 15:712-722.
24. WHO Histological classification of tumours of the lung. World health organization classification of tumours. pathology and genetics of tumours of the lung, pleura, thymus and heart 2004, IARC Press, Lyon (France). W.B. Travis, A. Brambilla, H.K. Muller-Hermelinck, C.C. Harris (Eds.).
25. Mountain C. Revisions in the international system for staging lung cancer. Chest 1997, 111:1710-1717.
26. Mountain C.F., Dresler C.M. Regional lymph node classification for lung cancer staging. Chest 1997, 111:1718-1723.
27. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 1982, 5:649-655.
28. Giraud P., Antoine M., Larrouy A., Milleron B., Callard P., De Rycke Y., et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 2000, 48:1015-1024.
29. Graham M.V., Purdy J.A., Emami B., Harms W., Bosch W., Lockett M.A., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999, 45:323-329.
30. WHO handbook for reporting results of cancer treatment 1979, World Health Organization offset Publication No. 48, Geneva (Switzerland).
31. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0. Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
32. Pavy J.J., Denekamp J., Letschert J., Littbrand B., Mornex F., Bernier J., et al. EORTC late effects working group. Late Effects toxicity scoring: the SOMA-LENT scale. Int J Radiat Oncol Biol Phys 1995, 31:1043-1047.
33. Bellissant E., Benichou J., Chastang C. The group sequential triangular test for phase II cancer clinical trials. Am J Clin Oncol 1996, 19:422-430.
34. Schemper M., Smith T.L. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:343-346.
35. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
36. Bardet E., Moro-Sibilot D., Le Chevalier T., Massard G., Douillard J.Y., Theobald S., et al. Standards, options and recommendations for the management of locally advanced non-small cell lung carcinoma. Bull Cancer 2001, 88:369-387.
37. Nakamura H., Taguchi M., Kitamura H., Nishikawa J. Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer. Gen Thorac Cardiovasc Surg 2008, 56:404-409.
38. Grunenwald D.H., André F., Le Péchoux C., Girard P., Lamer C., Laplanche A., et al. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 2000, 122:796-802.
39. DeCamp M.M., Rice T.W., Adelstein D.J., Chidel M.A., Rybicki L.A., Murthy S.C., et al. Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer. J Thorac Cardiovasc Surg 2003, 126:17-27.
40. Trodella L., Granone P., Valente S., Margaritora S., Macis G., Cesario A., et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol 2004, 15:389-398.
41. Vokes E.E., Herndon J.E., 2nd, Crawford J., Leopold K.A., Perry M.C., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002, 20:4191-4198.
42. Fleck J., Camargo J., Godoy D., Teixeira P., Graga-Filho A., Barletta A. Chemoradiation therapy alone versus chemotherapy alone as a neoadjuvant treatment for stage III non-small-cell lung cancer. Preliminary report of a phase III, randomized trial. Proc Am Soc Clin Oncol 1993, 11:1108. (abstract).
43. Thomas M., Rübe C., Hoffknecht P., Macha H.N., Freitag L., Linder A., et al. German Lung Cancer Cooperative Group. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 2008, 9:636-648.
44. Van Zandwijk N., Smit E.F., Kramer G.W., Schramel F., Gans S., Festen J., et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000, 18:2658-2664.
45. Albain K.S., Swann R.S., Rusch V.W., Turrisi A.T., Shepherd F.A., Smith C., et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009, 374:379-386.
46. van Meerbeeck J.P., Kramer G.W., Van Schil P.E., Legrand C., Smit E.F., Schramel F., et al. European organisation for research and treatment of cancer-lung cancer group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007, 99:442-450.
47. Betticher D.C., Hsu Schmitz S.F., Tötsch M., Hansen E., Joss C., von Briel C., et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003, 21:1752-1759.